Insider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells $357,372.56 in Stock

Posted by Amanda Harley on Apr 6th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $12.28, for a total transaction of $357,372.56. Following the completion of the transaction, the insider now owns 3,141,682 shares in the company, valued at approximately $38,579,854.96. This trade represents a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total value of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total transaction of $164,836.88.

Abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $11.43 on Friday. Abrdn Life Sciences Investors has a twelve month low of $11.41 and a twelve month high of $15.90. The firm’s 50-day moving average is $13.42 and its two-hundred day moving average is $14.02.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 16.45%. The ex-dividend date of this dividend was Friday, February 21st.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several hedge funds and other institutional investors have recently bought and sold shares of HQL. Sanctuary Advisors LLC increased its position in shares of Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after buying an additional 1,355 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Abrdn Life Sciences Investors by 7.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock valued at $1,199,000 after acquiring an additional 6,200 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new position in Abrdn Life Sciences Investors during the 4th quarter valued at about $160,000. Absolute Investment Advisers LLC acquired a new position in Abrdn Life Sciences Investors during the fourth quarter worth about $5,242,000. Finally, Wolverine Asset Management LLC acquired a new position in Abrdn Life Sciences Investors during the fourth quarter worth about $1,594,000. 32.21% of the stock is owned by institutional investors and hedge funds.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.